Navigation Links
BioMarin Announces FDA Approval for Kuvan
Date:12/13/2007

ired for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all PKU patients under the age of 40 in developed countries have been diagnosed at birth. Currently, PKU can only be managed by a Phe-restricted diet, which is supplemented by nutritional replacement products, like formulas and specially-manufactured foods; however, the strict diet is difficult for most patients to adhere to the extent needed for achieving adequate control of blood Phe levels. To learn more about PKU, please visit http://www.PKU.com. Information on this website is not incorporated by reference into this press release.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(TM) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the trea
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... August 31, 2015 A ... global cardiovascular monitoring and diagnostic devices market stood ... to reach a value of approximately US$7.0 billion ... between 2013 and 2019. The title of the ... (ECG, Holter Monitors, Event Monitors, Cardiovascular Diagnostic Catheters, ...
(Date:8/31/2015)... 31, 2015  Regulatory affairs professionals work at ... are often strict and legislation is ever-changing. The ... for professionals who have a deep understanding of ... product lifecycle and demonstrate its use across various ... California, Irvine Extension , in partnership with the ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. ... SNY ; EURONEXT: SAN) and the life sciences ... to improve care and outcomes for people with type ... in diabetes treatments and devices with Google,s expertise in ... companies will explore how to improve diabetes care by ...
Breaking Medicine Technology:Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6
... organizer UBM Live announced strong booking levels ... buyers and sellers of high value chemistry. 248 exhibitors ... takes place from February 19th to 22nd of 2013 ... fine and specialty chemical companies that have signed up ...
... 15, 2012  Adamas Pharmaceuticals, Inc., a privately held ... End-of-Phase 2 meeting with the FDA to discuss ... conducted for the registration of Arimenda (memantine HCl ... once-daily fixed dose combination of extended release memantine ...
Cached Medicine Technology:Strong Booking Levels For Informex 2013 2Strong Booking Levels For Informex 2013 3Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™ 2Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™ 3
(Date:8/31/2015)... ... September 01, 2015 , ... Spinal fusion surgery – which ... a long, arduous recovery. However, today’s minimally invasive fusions achieve similar results as ... minimal muscle damage. These advantages of minimally invasive surgery redeem the procedure’s reputation, ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... patients the resources they need to have a successful cosmetic procedure; from publishing ... surgeons; Cosmetic Town Journal is always ready to help. , It is clear ...
(Date:8/31/2015)... Beach, FL (PRWEB) , ... August 31, 2015 , ... ... of companies – has teamed up with fellow South Walton property management ... on eliminating extreme poverty in remote parts of the world. The two companies will ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... insurance, announced today their new “ InstantQuote ” tool, which summarizes all available ... easy-to-understand format. The technology tool is designed to help India Network members make ...
(Date:8/31/2015)... ... August 31, 2015 , ... Women’s Excellence in Wellness, ... to the Lake Orion area. This program is one of the most successful ... management program will incorporate group fitness and nutritional consultations to help people lose ...
Breaking Medicine News(10 mins):Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Cosmetic Town: A One Stop Plastic Surgery Community 2Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2
... how they help arteries stay clear and healthy , TUESDAY, ... researchers have begun to discover the exact molecular reasons why ... and ordinary orange juice are good for the health of ... studies describing the range of genes that are affected by ...
... , , OWINGS MILLS, Md., ... leading portion-controlled weight-loss program, today announced the launch of Honey Mustard ... and Parmesan Cheese Puffs. The new pretzel sticks and cheese puffs ... & 1 Plan, while also maintaining the nutritional value of Medifast ...
... to Treat Diseases (HTDS.PK) www.htdsmedical.com announced today ... the country of Thailand. The registration is expected to ... This registration is required to accommodate a customer from ... products such as MEVAC-A, MEVAC-DTaP, and MEVAC-ACYW. , Mellow ...
... N.H., July 21 Emerson Ecologics, LLC today announced that ... Michelle will develop and implement new business opportunities while maintaining ... , , "Michelle brings a ... this important new position," said Fran Towey, CEO of Emerson ...
... (July 21, 2009) Columbia University Medical Center,s Jeffrey ... of schizophrenia, has been selected by the National Institute ... Health as principal investigator of a nationwide effort to ... experiencing a first episode of the psychotic symptoms of ...
... Chinese patients will soon have the opportunity to take ... at reversing the autoimmune disease, ankylosing spondylitis. Approximately 200 ... trial that aims to merge the latest molecular discoveries ... with the medical expertise of physicians and researchers at ...
Cached Medicine News:Health News:Studies Show Genetic Activity of Antioxidants 2Health News:Studies Show Genetic Activity of Antioxidants 3Health News:Medifast Adds Pretzel and Puffs to Meal Replacement Line 2Health News:Medifast Adds Pretzel and Puffs to Meal Replacement Line 3Health News:Hard To Treat Diseases (HTDS.PK) Thailand Registration 2Health News:Emerson Ecologics Names Michelle Hebert New England Regional Sales Representative 2Health News:Columbia leads national effort to develop early intervention for schizophrenia 2Health News:Columbia leads national effort to develop early intervention for schizophrenia 3Health News:Study aims to induce recovery from ankylosing spondylitis 2
High intensity halogen lamp with built-in, switchable spare. Optical light concentrator to optimize existing light energy....
... biocompatible, flexible, one-piece artificial cornea (keratoprosthesis) designed ... cornea., ,The World Health Organisation (WHO) reports ... million people worldwide, however only 100,000 people ... is due to a combination of inadequate ...
PDA-version of the complete ICD-9 diagnosis codes....
PDA formatted guide containing outlines and detailed information on the diagnosis and treatment of HIV infection and AIDS....
Medicine Products: